Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.03 Million EUR | 5.65% |
| 2022 | 3.82 Million EUR | -40.37% |
| 2021 | 6.4 Million EUR | 4.82% |
| 2020 | 6.11 Million EUR | 31.57% |
| 2019 | 4.64 Million EUR | 50.88% |
| 2018 | 3.08 Million EUR | 38.05% |
| 2017 | 2.23 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 3.92 Million EUR | 29.66% |
| 2024 Q1 | 3.92 Million EUR | -2.9% |
| 2023 Q3 | 3.92 Million EUR | -8.78% |
| 2023 FY | 4.03 Million EUR | 5.65% |
| 2023 Q4 | 4.03 Million EUR | 2.85% |
| 2023 Q2 | 4.3 Million EUR | 2.35% |
| 2023 Q1 | 4.2 Million EUR | 10.02% |
| 2022 Q4 | 3.82 Million EUR | 0.21% |
| 2022 Q3 | 3.81 Million EUR | 44.96% |
| 2022 Q2 | 2.63 Million EUR | -38.04% |
| 2022 Q1 | 4.24 Million EUR | -33.75% |
| 2022 FY | 3.82 Million EUR | -40.37% |
| 2021 FY | 6.4 Million EUR | 4.82% |
| 2021 Q2 | 6.07 Million EUR | -3.14% |
| 2021 Q3 | 7.89 Million EUR | 30.02% |
| 2021 Q4 | 6.4 Million EUR | -18.83% |
| 2021 Q1 | 6.27 Million EUR | 2.55% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 6.11 Million EUR | -3.14% |
| 2020 Q3 | 6.31 Million EUR | 0.0% |
| 2020 FY | 6.11 Million EUR | 31.57% |
| 2019 FY | 4.64 Million EUR | 50.88% |
| 2018 FY | 3.08 Million EUR | 38.05% |
| 2017 FY | 2.23 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -19.115% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 92.72% |
| Adocia SA | 13.08 Million EUR | 69.147% |
| Biophytis S.A. | 8.27 Million EUR | 51.173% |
| Advicenne S.A. | 17.42 Million EUR | 76.826% |
| genOway Société anonyme | 7.23 Million EUR | 44.176% |
| IntegraGen SA | 1.12 Million EUR | -259.018% |
| Medesis Pharma S.A. | 1.2 Million EUR | -236.5% |
| Neovacs S.A. | 650 Thousand EUR | -521.231% |
| NFL Biosciences SA | 62.17 Thousand EUR | -6394.676% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 7.311% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -48.629% |
| Sensorion SA | 2.86 Million EUR | -40.756% |
| Theranexus Société Anonyme | 3.64 Million EUR | -10.842% |
| TME Pharma N.V. | 1.16 Million EUR | -246.312% |
| Valbiotis SA | 6.87 Million EUR | 41.291% |
| TheraVet SA | 1.15 Million EUR | -248.143% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 55.123% |
| argenx SE | 18.1 Million EUR | 77.697% |
| BioSenic S.A. | 28.16 Million EUR | 85.661% |
| Celyad Oncology SA | 902 Thousand EUR | -347.672% |
| DBV Technologies S.A. | 13.01 Million USD | 68.983% |
| Galapagos NV | 9.59 Million EUR | 57.92% |
| Genfit S.A. | 70.17 Million EUR | 94.246% |
| GeNeuro SA | 7.73 Million EUR | 47.815% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 23.725% |
| Innate Pharma S.A. | 39.89 Million EUR | 89.878% |
| Inventiva S.A. | 37.4 Million EUR | 89.205% |
| MaaT Pharma SA | 14.07 Million EUR | 71.311% |
| MedinCell S.A. | 58.96 Million EUR | 93.151% |
| Nanobiotix S.A. | 50.56 Million EUR | 92.014% |
| Onward Medical N.V. | 16.87 Million EUR | 76.07% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 70.498% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 91.184% |
| Oxurion NV | 12.33 Million EUR | 67.261% |
| Pharming Group N.V. | 155.29 Million EUR | 97.4% |
| Poxel S.A. | 46.9 Million EUR | 91.39% |
| GenSight Biologics S.A. | 18.42 Million EUR | 78.088% |
| Transgene SA | 1.25 Million EUR | -221.241% |
| Financière de Tubize SA | 79.2 Million EUR | 94.902% |
| UCB SA | 3.03 Billion EUR | 99.867% |
| Valneva SE | 208.81 Million EUR | 98.066% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -10526.316% |